Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
once-weekly cagrilintide-semaglutide (2.4 mg each) | decrease | body weight | adults with obesity and type 2 diabetes | - | resulted in a significantly lower | #1 |
once-weekly cagrilintide-semaglutide (2.4 mg each) | decrease | body weight from baseline to week 68 | patients | -13.7% | estimated mean change | #2 |
placebo | decrease | body weight from baseline to week 68 | patients | -3.4% | estimated mean change | #3 |
once-weekly cagrilintide-semaglutide (2.4 mg each) | decrease | body weight change | - | -10.4 percentage points | estimated difference | #4 |
once-weekly cagrilintide-semaglutide (2.4 mg each) | decrease | weight reduction of 5% or more | patients | - | more patients had | #5 |
once-weekly cagrilintide-semaglutide (2.4 mg each) | decrease | weight reduction of at least 10% | patients | - | more patients had | #6 |
once-weekly cagrilintide-semaglutide (2.4 mg each) | decrease | weight reduction of at least 15% | patients | - | more patients had | #7 |
once-weekly cagrilintide-semaglutide (2.4 mg each) | decrease | weight reduction of at least 20% | patients | - | more patients had | #8 |
once-weekly cagrilintide-semaglutide (2.4 mg each) | decrease | glycated hemoglobin level of 6.5% or less | patients | 73.5% | percentage of patients who had | #9 |
placebo | decrease | glycated hemoglobin level of 6.5% or less | patients | 15.9% | percentage of patients who had | #10 |
once-weekly cagrilintide-semaglutide (2.4 mg each) | increase | gastrointestinal adverse events | patients | 72.5% | gastrointestinal adverse events were reported by | #11 |
placebo | increase | gastrointestinal adverse events | patients | 34.4% | gastrointestinal adverse events were reported by | #12 |
BACKGROUND: Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring. METHODS: In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placebo, along with lifestyle intervention, for 68 weeks. The two primary end points were the percent change in body weight and the percentage of patients with a weight reduction of at least 5%. Additional end points were changes in glycemic measures and safety assessments. Effect estimates were calculated with the use of the treatment-policy estimand (consistent with the intention-to-treat principle). RESULTS: A total of 1206 patients underwent randomization to either the cagrilintide-semaglutide group (904 patients) or the placebo group (302 patients). The estimated mean change in body weight from baseline to week 68 was -13.7% in the cagrilintide-semaglutide group and -3.4% in the placebo group (estimated difference, -10.4 percentage points; 95% confidence interval, -11.2 to -9.5; P<0.001). More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was true of reductions of at least 10%, 15%, and 20% (P<0.001 for the last comparison). The percentage of patients who had a glycated hemoglobin level of 6.5% or less was 73.5% in the cagrilintide-semaglutide group and 15.9% in the placebo group. Gastrointestinal adverse events were reported by 72.5% of the patients in the cagrilintide-semaglutide group and 34.4% in the placebo group, most of which were transient and mild or moderate in severity. CONCLUSIONS: Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes. (Funded by Novo Nordisk; REDEFINE 2 ClinicalTrials.gov number, NCT05394519.).